InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,840.58
(
0.07%
)
Post# of 251796
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: None

Wednesday, 07/10/2013 11:04:52 PM

Wednesday, July 10, 2013 11:04:52 PM

Post# of 251796
ARQL @ JMP (7/10/13)

1. In regards to P3 tivantinib HCC trial, stratification factors include: vascular invasion, extra-hepatic spread, and AFP.

2. ARQL plans to provide update on P3 MARQUEE NSCLC trial data at ESMO this year. Per slide 13 and based on a recent exploratory analysis, there was a substantial improvement in OS and PFS in 211 MET-high patients. There was no difference in OS in 234 MET-low patients. There was similar PFS in MET-high and MET-low patients.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up